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Closer to closing the loop on inpatient glycaemia
Automated systems that deliver safer patient care are 
becoming increasingly important in health care and 
particularly in disorders such as diabetes, where therapy 
needs to be dynamically matched to physiological 
and metabolic measures. An area of particular interest 
is diabetes in inpatients, in whom establishing and 
maintaining good metabolic control is challenging yet 
important, because there is increasing evidence for the 
beneﬁ ts of good glycaemic control on length of hospital 
stay, patient outcomes, and cost savings.1 This problem is 
sizeable because the prevalence of diabetes in inpatients 
is three times greater than in the general population, 
and the UK’s National Diabetes Inpatient Audit (NaDIA) 
projects that the number of hospital beds occupied by 
people with diabetes will increase to nearly 20% by 2020; 
in many hospitals it already exceeds 30%.2 More than 
90% of inpatients with diabetes have type 2 diabetes, 
and about 30% are receiving insulin therapy. Good 
glycaemic control in insulin-treated inpatients is achieved 
less than 40% of the time and one in ten patients has 
a severe hypoglycaemia (blood glucose <3 mmol/L) 
episode during their hospital stay.2 Hypoglycaemia 
and hyperglycaemia in inpatients are associated with 
increased morbidity, mortality, and length of hospital 
stay.3–5 Although there have been improvements in 
glycaemic control since the ﬁ rst NaDIA, these have been 
fairly small. There is considerable need for systems to help 
safely achieve better glycaemic control.
In this issue of The Lancet Diabetes & Endocrinology, 
Hood Thabit and colleagues6 report that for insulin-
treated inpatients with type 2 diabetes, a fully 
automated closed-loop system signiﬁ cantly increased 
time in the glycaemic target range compared with 
conventional subcutaneous insulin delivery (59·8% 
[SD 18·7] in the closed-loop group vs 38·1% [16·7] in 
the control group; diﬀ erence 21·8% [95% CI 10·4–33·1]; 
p<0·001). Additionally, the closed-loop intervention 
reduced the frequency of hyperglycaemia without an 
increase in hypoglycaemia or total daily insulin dose. 
This system is a welcome advance; however, further 
work is required to determine the practicalities, safety, 
ease of use, and cost in the larger population of insulin-
treated inpatients with type 2 diabetes.
Although the investigators encountered no 
safety issues in what they describe as a “real-world” 
environment, only 20 individuals with type 2 diabetes 
were studied. Findings in larger numbers of patients are 
needed before the system’s safety can be established 
with conﬁ dence. Furthermore, most of the patients 
in the study had diabetic foot disease, whereas many 
insulin-treated type 2 inpatients will have additional 
complex comorbidities, which might inﬂ uence 
treatment response. Perhaps the most important 
question relates to the practicality and ease of use of the 
intervention on general wards. By the nature of patients 
in the study, it is likely that they will have had input from 
the diabetes specialist team and many, if not all, will 
have been cared for on a diabetes or vascular ward with 
close monitoring by the study team. This situation is 
understandable for a pilot study but does not represent 
the real world, in which 85% of diabetes admissions are 
emergencies unrelated to diabetes, and patients are not 
under the care of the diabetes team.2 Nearly all patients 
with insulin-treated type 2 diabetes will have their initial 
insulin therapy managed by non-specialist teams, and 
in the UK most will not be seen by a member of the 
diabetes specialist team during their stay. Indeed, the 
shortage of inpatient diabetes services in the UK means 
that diabetes specialist teams see only 60% of patients 
requiring their expertise, and 30% of hospital trusts have 
no inpatient diabetes specialist nurses.2
So where does this new technology sit in the real 
world? If it is to be generalised, nurses on non-specialist 
wards will have to be trained to use the closed-loop 
system, including inserting and calibrating the sensor, 
which is not always straightforward and sensor failure 
is common even in the hands of diabetes specialists. In 
the current study, 35% of the sensors had to be replaced, 
the majority because of sensor failure; in the hands of 
non-technologists failure rates will be greater. Sensor 
dislodgment might also be frequent in general use, since 
as many as 30% of inpatients with diabetes have cognitive 
impairment.2 Fitting and recalibrating new sensors will 
add to the cost and could be seen as an additional burden 
by hard-pressed nursing staﬀ . It may well be true that the 
closed-loop system will reduce staﬀ  workload because no 
prandial insulin is required, as the investigators suggest, 
but this needs to be determined in practice.
In the study by Thabit and colleagues, patients in 
the comparison group were kept on their usual insulin 
Comment
2 www.thelancet.com/diabetes-endocrinology   Published online November 8, 2016   http://dx.doi.org/10.1016/S2213-8587(16)30327-8
regimen, which might not have been optimal. Only 55% 
were on a basal bolus regimen, which is recommended 
in the USA and is associated with lower complication 
rates, the rest were on either a basal only or twice daily 
premixed insulin regimen.7–9 Of relevance, a recent 
study in 99 patients with type 2 diabetes (80% who 
were insulin treated) managed on multiple wards with a 
basal-bolus regimen driven by a computerised decision 
support system achieved a time in the target glucose 
range of 50·2% (SD 22·2) for a target of 3·9–7·8 mmol/L, 
compared with 59·8% (SD 18·7) in the closed-loop group 
of the present study for a target of 5·6–10·0 mmol/L.10 
Further studies will be required to determine the beneﬁ ts 
of the closed-loop system against such systems.
The greatest potential beneﬁ t of closed-loop systems 
is the avoidance of hypoglycaemia while preventing 
hyperglycaemia. That this beneﬁ t could not be 
demonstrated probably relates to the unusually low 
frequency of hypoglycaemia in the control group as 
well as the small number of patients in the study. This 
limitation yet again makes the case for a larger study.
Thabit and colleagues should be congratulated on the 
control algorithm, which worked well in the patients 
studied. They have already demonstrated that the sensor 
performs well in the intensive care setting in patients 
with renal, cardiac and respiratory failure.11 Furthermore, 
in a small study12 they showed that closed loop system 
performed better than an intravenous insulin infusion 
algorithm, in critical care patients. These are exciting 
developments however; both studies must be viewed 
as proof of concept studies. Larger studies are required 
and the ease of use of subcutaneous insulin pumps and 
sensors will need to be addressed before the closed-loop 
system can be rolled out to non-specialist inpatient teams.
Gerry Rayman
The Ipswich Hospital NHS Trust, Diabetes and Endocrine Centre, 
Ipswich, Suﬀ olk IP4 5PD, UK
Gerry.rayman@ipswichhospital.nhs.uk
We declare no competing interests.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access 
article under the CC BY license.
1 Ahmann A. Reduction of hospital costs and length of stay by good control 
of blood glucose levels. Endocr Pract 2004; 10 (suppl 2): 53–56.
2 Health and Social Care Information Centre (HSCIC), NHS UK. National 
diabetes inpatient audit 2014. http://www.ic.nhs.uk/
diabetesinpatientaudit (accessed Oct 19, 2016).
3 Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent 
marker of in-hospital mortality in patients with undiagnosed diabetes. 
J Clin Endocrinol Metab 2002; 87: 978–82.
4 Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, 
Pendergrass ML. Hypoglycemia and clinical outcomes in patients with 
diabetes hospitalized in the general ward. Diabetes Care 2009; 32: 1153–57.
5 Nirantharakumar K, Marshall T, Kennedy A, Narendran P, Hemming K, 
Coleman JJ. Hypoglycaemia is associated with increased length of stay and 
mortality in people with diabetes who are hospitalized. Diabet Med 2012; 
29: e445–48.
6 Thabit H, Hartnell S, Allen JM, et al. Closed-loop insulin delivery in 
inpatients with type 2 diabetes: a randomised, parallel-group trial. 
Lancet Diabetes Endocrinol 2016; published online Nov 8. http://dx.doi.
org/10.1016/S2213-8587(16)30280-7.
7 American Diabetes Association. Diabetes care in the hospital. Diabetes Care 
2016; 39 (suppl 1): S99–S104.
8 Umpierrez GE, Smiley D, Hermayer K, et al. Randomized study comparing a 
basal-bolus with a basal plus correction insulin regimen for the hospital 
management of medical and surgical patients with type 2 diabetes: basal 
plus trial. Diabetes Care 2013; 36: 2169–74.
9 Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus 
insulin therapy in the inpatient management of patients with type 2 
diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 
2011; 34: 256–61.
10 Neubauer KM, Mader JK, Höll B, et al. Standardized glycemic management 
with a computerized workﬂ ow and decision support system for 
hospitalized patients with type 2 diabetes on diﬀ erent wards. 
Diabetes Technol Ther 2015; 17: 685–92.
11 Leelarathna L, English SW, Thabit H, et al. Accuracy of subcutaneous 
continuous glucose monitoring in critically ill adults: improved sensor 
performance with enhanced calibrations. Diabetes Technol Ther 2014; 
16: 97–101.
12 Leelarathna L, English SW, Thabit H, et al. Feasibility of fully automated 
closed-loop glucose control using continuous subcutaneous glucose 
measurements in critical illness: a randomized controlled trial. Crit Care 
2013; 17: R159.
